Transitioning From Vial To Prefilled Syringe: How Formulation Development Affects Manufacturing

Source: Catalent

By Natasha Van Rutten, Product Development Director, Catalent Biologics


Due to advances in technology and increased development of parenteral drugs, one of the fastest growing choices for drug delivery in the pharmaceutical industry is the prefilled syringe (PFS).1 Not only can PFSs help cut manufacturing and product costs for pharmaceutical companies, but they also offer significant benefits to the physician and patient. However, before taking advantage of these benefits, it is important to understand how formulation development for a PFS affects manufacturing. Doing so can drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Delivery Leader? Subscribe today.

Subscribe to Drug Delivery Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Delivery Leader